Amarna Therapeutics Raises €10M in Funding

healthcareAmarna Therapeutics, a Leiden, the Netherlands-based biotechnology company, raised €10m in funding.

The round was led by Flerie Invest AB with an innovation credit coming from the “Netherlands Enterprise Agency” ( and existing shareholder Pim Berger.

The company plans to use this funding to progress development of its SVac platform towards a first-in-man clinical study to commence in two to three years from now.

Founded in 2008 and led by Ben van Leent, CEO, Amarna Therapeutics is a biotech company that is developing a next-generation SV40-based gene delivery vector platform named SVac that aims to transform gene-replacement and immunotherapy across many disease areas including genetic disorders, degenerative/inflammatory/autoimmune diseases, infectious diseases and cancer.
The company, which also has a research facility in Seville, Spain, has genetically engineered the SV40 genome used for the production of vector particles and in parallel generated a novel Vero-based packaging cell line named SuperVero that produces similar numbers of vector particles to the currently used packaging cell lines but without contaminating wild type SV40 particles.



Join the discussion